Iluvien

Type: Product
Name: Iluvien
First reported Oct 09 2014 - Updated Oct 09 2014 - 2 reports

Alimera Sciences to Present at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting

SOURCE Alimera Sciences, Inc.CEO to Discuss Milestone FDA Approval of ILUVIEN as the First Long-Term Treatment for Diabetic Macular EdemaATLANTADan MyersA copy of the presentation will be available on the Investor Relations section of the corporate website, ... [Published KSWT13 - Oct 09 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

Alimera’s Thrice-Rejected Eye Drug Iluvien Finally Gets FDA Approval

Alimera Sciences has won FDA approval of its eye drug Iluvien after several years of negotiations with the agency to address potential safety concerns.Iluvien (fluocinolone acetonide intravitreal implant) is indicated to treat diabetic macular edema ... [Published FDA News - Oct 01 2014]
First reported Sep 30 2014 - Updated Oct 01 2014 - 2 reports

Why Alimera Sciences (ALIM) Stock Is Up Today

09/30/14 - 04:14 PM EDTNEW YORK ( TheStreet ) -- Shares of Alimera Sciences Inc. ( ALIM )  closed up 1.69% to $5.42 on Tuesday after the company announced it had received a $25 million advance from Hercules Technology Growth Capital  ( HTGC ) .The advance ... [Published TheStreet.com - Sep 30 2014]
First reported Sep 30 2014 - Updated Oct 01 2014 - 3 reports

Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital

ATLANTAAlimera will use the advance to fund a $25 million milestone payment owed to the licensor of certain intellectual properly as a result of the recent FDA approval of ILUVIEN®.Interest on outstanding borrowings under the term loan is payable at the ... [Published Bio-Medicine - Oct 01 2014]
First reported Sep 30 2014 - Updated Oct 01 2014 - 2 reports

pSivida Secures FDA Approval of ILUVIEN for Diabetic Macular Edema

pSivida Corp. reported that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN for the treatment of diabetic macular edema (DME). According to a company release, FDA approval of ILUVIEN entitles pSivida to a $25 million milestone from its ... [Published Individual.com - Oct 01 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 2 reports

Morning Market Movers

Ambit Biosciences (NASDAQ: AMBI) shares jumped 87.56% to $15.38 after Daiichi Sankyo (OTC: DSNKY) announced its plans to acquire Ambit Biosciences for $15 per share in cash through a tender offer.Athlon Energy (NYSE: ATHL) shares gained 24.67% to $58.26 ... [Published Benzinga.com - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 4 reports

Alimera/pSivida's Iluvien Receives FDA Approval for DME

Alimera Sciences, Inc. ’s long wait ended when the FDA finally approved Iluvien for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids. A clinically significant rise in intraocular ... [Published Zacks.com - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Alimera Sciences (ALIM) leaps as FDA gives OK

Alimera Sciences (NASDAQ: ALIM) jumped 15.3% to $5.66 after the company confirmed the FDA approval for ILUVIEN. The company expected to begin selling ILUVIEN in the U.S. during the first quarter of 2015. Share volume was 368,000, compared to an all-day ... [Published BayStreet.ca - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 11 reports

Eye Implant Iluvien for Diabetic Macular Edema Clears FDA

(Reuters) - The Food and Drug Administration has approved eye implant Iluvien, from Alimera Sciences and pSivida Corp, for treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did ... [Published Diabetes Care - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

AMBI Snapped Up, ALIM's Iluvien Gets FDA Nod, GLYC Faces Glitch In Study

AbbVie Inc.'s (ABBV: Quote) ongoing phase II study of its investigational compound Veliparib in combination with chemotherapy has demonstrated a 35 percent improvement in progression-free survival and a 30 percent improvement in overall survival in patients ... [Published RTTNews.com - Sep 29 2014]
First reported Sep 26 2014 - Updated Sep 27 2014 - 20 reports

Here’s Why Alimera And pSivida Surged In Extended Trading

Alimera Sciences gained 23% in extended trading on FDA approval for its diabetic macular edema treatment— IluvienPage 1 of 2Published: September 27, 2014 at 8:40 am EST By: Hannah Ishmael Click Ticker to See live coverage ALIM PSDV REGN RHHBYAlimera ... [Published Bidness Etc - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

pSivida Corp. Reports FDA Approval of ILUVIEN(R) -2-

molecules; ability to develop product candidates and products and potential related collaborations; initiation and completion of clinical trials and obtaining regulatory approval of product candidates; continued sales of Retisert; adverse side effects; ... [Published Scottrade - Sep 26 2014]

Quotes

...approval in seventeen other EU countries, for the treatment of patients with the chronic DME insufficiently responsive to available therapies. "We are very pleased that the FDA's approval of ILUVIEN is not limited, as in the EU, to the subset of patients with chronic DME, patients who have failed other therapies, or patients who have had cataract surgery" continued Dr. Ashton
"We rate ALIMERA SCIENCES INC (ALIM) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its disappointing return on equity."
"Corticosteroids have a history of effective use in treating ocular disease inflammation. Iluvien is injected in the back of the patient's eye with an applicator that employs a 25-gauge needle, which allows for a self-sealing wound" according to a company release
"The approval of Iluvien under this broader label brings a DME treatment to the U S that lasts years, not months, after a single injection and greatly expands the addressable market opportunity in the U S " CEO Dan Myers said in a statement

More Content

All (91) | News (63) | Reports (0) | Blogs (28) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Subspecialty News: Fovista Combats Subretinal F... [Published Retinal Physician - Oct 10 2014]
Alimera Sciences to Present at Ophthalmology In... [Published KSWT13 - Oct 09 2014]
Alimera Sciences to Present at Ophthalmology In... [Published Stockhouse Canada - Oct 09 2014]
Alimera Sciences to Present at Ophthalmology In... [Published Barchart - Oct 09 2014]
East Coast Biotech Roundup: Intarcia, Atlas, Vi... [Published Xconomy - Oct 06 2014]
Allergan’s Ozurdex Granted New DME Indication [Published FDA News - Oct 04 2014]
Alimera’s Thrice-Rejected Eye Drug Iluvien Fina... [Published FDA News - Oct 01 2014]
Eylea receives European approval for treating D... [Published Diabetes.co.uk - Oct 01 2014]
Alimera Sciences Receives $25 Million Advance f... [Published Bio-Medicine - Oct 01 2014]
Hercules Technology Growth Capital issues advan... [Published News-Medical.Net - Oct 01 2014]
pSivida Secures FDA Approval of ILUVIEN for Dia... [Published Individual.com - Oct 01 2014]
Why Alimera Sciences (ALIM) Stock Is Up Today [Published TheStreet.com - Sep 30 2014]
Why Alimera Sciences (ALIM) Stock Is Up Today [Published The Street Latest - Sep 30 2014]
Alimera Sciences Receives $25 Million Advance f... [Published Scottrade - Sep 30 2014]
FDA Approves First Long-Term Diabetic Macular E... [Published Pharmacy Times - Sep 30 2014]
Lower close as protests continue in Hong Kong [Published CEOWorld Magazine - Sep 29 2014]
BARCHART MORNING CALL 9/29 [Published Seeking Alpha - Sep 29 2014]
Alimera/pSivida's Iluvien Receives FDA Approval... [Published Zacks.com - Sep 29 2014]
Monday's most followed in U.S. including DreamW... [Published Proactive Investors USA - Sep 29 2014]
Why Alimera Sciences (ALIM) Stock Is Gaining Today [Published TheStreet.com - Sep 29 2014]
Why Alimera Sciences (ALIM) Stock Is Gaining Today [Published The Street Latest - Sep 29 2014]
Fourth time's the charm: pSivida, Alimera jump ... [Published MassDevice - Sep 29 2014]
Eye Implant Iluvien for Diabetic Macular Edema ... [Published Diabetes Care - Sep 29 2014]
FDA approves Iluvien for treatment of DME [Published Orthopedics Today - Sep 29 2014]
Will Analysts Start Following Alimera After Its... [Published 24/7 Wall St - Sep 29 2014]
Alimera Sciences Inc Extends Gains On FDA News [Published Benzinga.com - Sep 29 2014]
Will Analysts Start Following Alimera After Its... [Published 24/7 Wall St. - Sep 29 2014]
Alimera Sciences (ALIM) leaps as FDA gives OK [Published BayStreet.ca - Sep 29 2014]
Alimera and pSivida finally win FDA approval fo... [Published FierceBiotech - Sep 29 2014]
BUZZ-U.S. Stocks on the Move-Ambit, Athlon, Ton... [Published Reuters - Sep 29 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Will Analysts Start Following Alimera After Its... [Published 24/7 Wall St. - Sep 29 2014]
Alimera Sciences traded up big on Monday on news that the company received FDA approval for its diabetic macular edema drug Iluvien. ...
Alimera Sciences Provides Details On FDA Approv... [Published PR Newswire: Policy & Public Interest - Sep 29 2014]
ATLANTA, Sept. 29, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it ...
Alimera's ILUVIEN gets FDA approval for diabeti... [Published PBR - News - Sep 29 2014]
Alimera Sciences has received approval from the US Food and Drug Administration (FDA) for ILUVIEN (fluocinolone acetonide intravitreal implant) to treat diabetic macular edema (DME). ...
Alimera Sciences Receives FDA Approval For ILUV... [Published PR Newswire: Policy & Public Interest - Sep 26 2014]
ATLANTA, Sept. 26, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the ...
pSivida Corp. Reports FDA Approval of ILUVIEN® ... [Published EON Science - Sep 26 2014]
WATERTOWN, Mass.--(EON: Enhanced Online News)--pSivida Reports FDA approval of ILUVIEN for Diabetic Macular Edema - pSivida earns $25 million milestone payment ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.